Clinical trialPhase 1Completed
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
A Phase I/II Trial of Intratumoral Dendritic Cell Immunotherapy in Combination With Gemcitabine and Stereotactic Radiosurgery in Unresectable Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- October 2005
- Expected end
- April 2008
- Enrollment
- 2 participants
- Sites
- 1
- Primary outcomes
- o evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells.; Phase II: To determine the overall response rate for this regimen as determined by radiographic criteria.; Phase I: To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with gemcitabine and stereotactic radiosurgery; To determine the time to tumor progression for this regimen.
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 November 2012
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer